An in vitro diagnostics firm with a primary focus on molecular diagnostics & genetic testing, NanoIVD Inc. is organized around blood-based tests for early cancer screening, cancer-recurrence monitoring, treatment-effectiveness monitoring, and personalized molecular cancer profiling for therapeutic selection. The firm maintains an algorithm for cancer biomarker selection and proprietary nanowire field-effect-transistor chip technology for label-free, real-time in-vitro diagnostic testing. NanoIVD's products have applications in early detection and profiling of cancer and other cell detection. The firm is an early development-stage biomedical company working to develop blood-based test, PanOncoâ¢. PanOnco⢠- a âliquid biopsyâ in-vitro diagnostic assay for early detection of clinically-significant (aggressive) cancers that can be used for determining cancer presence and the molecular pathway associated with the cancer for improved clinical decision-making in the care of cancer patient. The panel test is comprised of 8 protein biomarkers linked to cytoskeleton remodeling, cell migration, angiogenesis, anti-apoptosis, glucose metabolism, cellular proliferation, and immune escape, believed to be central to many types of cancer. The first indication (intended use) of PanOnco⢠for FDA clearance is for prostate cancer. Other NanoIVD works include a small molecule drug for Alzheimerâs disease and highly expressed and exclusively cancer specific proteins from the central cancer pathway for making antibody-drug conjugate. The company also has a flexible multiplex nanowire biosensor platform for developing blood-based tests for othe
